My Business Member Account
Business Member Portal
On this page, you can update your details, access training courses, and find other helpful resources to support your business membership of Anaphylaxis UK.
How are we doing?
Since our rebranding and new website in July 2022, we’ve already reached a staggering number of page views.
Our latest social media campaign reached over 650,000 unique people in 10 weeks with nearly 12,000 views on the campaign page and nearly 2,000 sign-ups to the campaign email.
Our Facebook page reaches 489,000 people and our organic post reach is over 72,500.
Our monthly newsletter has an open rate of over 56%.
Download
Download the Anaphylaxis UK Business Member logos along with the Brand Guidelines. Please use the Brand Guidelines on how to correctly display the logos and link to the Anaphylaxis Homepage: https://www.anaphylaxis.org.uk/
The Anaphylaxis UK Business Member logos
The Anaphylaxis UK Brand Guidelines
Exclusive training
Access training for you and colleagues here. The training courses are only available to Business Members.
Business News
Get the latest news. To feature news of your own, get in touch!
-
Covid-19 vaccine passports: concerns from an allergy perspective
As the Covid-19 vaccine roll-out continues apace in the UK, increasingly publicity has been given to the proposal that some form of certificate or ‘passport’ may be implemented, linked to the identity of the holder, to verify vaccination status and allow access to public venues, large gatherings, travel and other public arenas thereby, in theory,…
-
The Food Standards Agency Food Hypersensitivity Symposium
On the 23rd and 24th March, the Food Standards Agency (FSA) held their second annual Food Hypersensitivity Symposium which brought together delegates from a variety of backgrounds including food business operators, local authority enforcement, clinical allergy specialists and allergy patient organisations. The Anaphylaxis Campaign was delighted to attend and to contribute to the interactive workshops…
-
JCVI recommends that adults living with adults who are immunosuppressed should be prioritised for the COVID-19 vaccine
The Joint Committee on Vaccination and Immunisation (JCVI) has advised the government to prioritise people for the coronavirus (COVID-19) vaccine who are over 16 and living with adults who have weakened immune systems, such as those with blood cancer, HIV or those on immunosuppressive treatment including chemotherapy. Adults who are immunosuppressed have a weaker immune…
Business Member services and products
Some of our Business Members are featured here.
-
Support an AllergyWise® School£300.00 inc. VAT
